1. Home
  2. RLAY vs MSDL Comparison

RLAY vs MSDL Comparison

Compare RLAY & MSDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLAY
  • MSDL
  • Stock Information
  • Founded
  • RLAY 2015
  • MSDL 2019
  • Country
  • RLAY United States
  • MSDL United States
  • Employees
  • RLAY N/A
  • MSDL N/A
  • Industry
  • RLAY Biotechnology: Biological Products (No Diagnostic Substances)
  • MSDL
  • Sector
  • RLAY Health Care
  • MSDL
  • Exchange
  • RLAY Nasdaq
  • MSDL NYSE
  • Market Cap
  • RLAY 576.1M
  • MSDL 1.7B
  • IPO Year
  • RLAY 2020
  • MSDL N/A
  • Fundamental
  • Price
  • RLAY $3.60
  • MSDL $19.25
  • Analyst Decision
  • RLAY Strong Buy
  • MSDL Hold
  • Analyst Count
  • RLAY 11
  • MSDL 5
  • Target Price
  • RLAY $18.40
  • MSDL $20.00
  • AVG Volume (30 Days)
  • RLAY 1.5M
  • MSDL 431.0K
  • Earning Date
  • RLAY 08-05-2025
  • MSDL 01-01-0001
  • Dividend Yield
  • RLAY N/A
  • MSDL 11.43%
  • EPS Growth
  • RLAY N/A
  • MSDL N/A
  • EPS
  • RLAY N/A
  • MSDL N/A
  • Revenue
  • RLAY $7,679,000.00
  • MSDL N/A
  • Revenue This Year
  • RLAY $17.59
  • MSDL $1,597.39
  • Revenue Next Year
  • RLAY N/A
  • MSDL $15.10
  • P/E Ratio
  • RLAY N/A
  • MSDL N/A
  • Revenue Growth
  • RLAY N/A
  • MSDL N/A
  • 52 Week Low
  • RLAY $1.78
  • MSDL $17.59
  • 52 Week High
  • RLAY $10.72
  • MSDL $23.63
  • Technical
  • Relative Strength Index (RSI)
  • RLAY 57.25
  • MSDL 50.38
  • Support Level
  • RLAY $3.50
  • MSDL $18.84
  • Resistance Level
  • RLAY $3.86
  • MSDL $19.19
  • Average True Range (ATR)
  • RLAY 0.18
  • MSDL 0.28
  • MACD
  • RLAY 0.02
  • MSDL 0.02
  • Stochastic Oscillator
  • RLAY 65.79
  • MSDL 75.95

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

Share on Social Networks: